{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T05:14:24Z","timestamp":1793682864375,"version":"4.5.1"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Antipsychotic-induced hyperprolactinemia (AP-induced HPRL) occurs overall in up to 70% of patients with schizophrenia, which is associated with hypogonadism and sexual dysfunction. We summarized the latest evidence for the benefits of prolactin-lowering drugs. We performed network meta-analyses to summarize the evidence and applied Grading of Recommendations Assessment, Development, and Evaluation frameworks (GRADE) to rate the certainty of evidence, categorize interventions, and present the findings. The search identified 3,022 citations, 31 studies of which with 1999 participants were included in network meta-analysis. All options were not significantly better than placebo among patients with prolactin (PRL) less than 50\u2009ng\/ml. However, adjunctive aripiprazole (ARI) (5\u2009mg: MD\u2009=\u2009\u221264.26, 95% CI\u2009=\u2009\u221287.00 to \u221241.37; 10\u2009mg: MD\u2009=\u2009\u221259.81, 95% CI\u2009=\u2009\u221290.10 to \u221229.76; more than 10\u2009mg: MD\u2009=\u2009\u221268.01, 95% CI\u2009=\u2009\u221297.12 to \u221239.72), switching to ARI in titration (MD\u2009=\u2009\u221274.80, 95% CI\u2009=\u2009\u2212134.22 to \u221215.99) and adjunctive vitamin B6 (MD\u2009=\u2009\u221291.84, 95% CI\u2009=\u2009\u2212165.31 to \u221217.74) were associated with significant decrease in AP-induced PRL among patients with PRL more than 50\u2009ng\/ml with moderated (adjunctive vitamin B6) to high (adjunctive ARI) certainty of evidence. Pharmacological treatment strategies for AP-induced HPRL depends on initial PRL level. No effective strategy was found for patients with AP-induced HPRL less than 50\u2009ng\/ml, while adjunctive ARI, switching to ARI in titration and adjunctive high-dose vitamin B6 showed better PRL decrease effect on AP-induced HPRL more than 50\u2009ng\/ml.<\/jats:p>","DOI":"10.1038\/s41398-022-02027-4","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T04:05:42Z","timestamp":1656993942000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Pharmacological treatment strategies for antipsychotic-induced hyperprolactinemia: a systematic review and network meta-analysis"],"prefix":"10.1038","volume":"12","author":[{"given":"Zhe","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoyao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyanan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4223-7551","authenticated-orcid":false,"given":"Liangkun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yundan","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3722-3713","authenticated-orcid":false,"given":"Zhewei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1201-8465","authenticated-orcid":false,"given":"Weihua","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,5]]},"reference":[{"key":"2027_CR1","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1016\/S0140-6736(20)31544-0","volume":"396","author":"RS McIntyre","year":"2020","unstructured":"McIntyre RS, Berk M, Brietzke E, Goldstein BI, L\u00f3pez-Jaramillo C, Kessing LV, et al. Bipolar disorders. Lancet. 2020;396:1841\u201356.","journal-title":"Lancet"},{"key":"2027_CR2","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/S0140-6736(15)01121-6","volume":"388","author":"MJ Owen","year":"2016","unstructured":"Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet. 2016;388:86\u201397.","journal-title":"Lancet."},{"key":"2027_CR3","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.4088\/JCP.v65n1108","volume":"65","author":"J Montgomery","year":"2004","unstructured":"Montgomery J, Winterbottom E, Jessani M, Kohegyi E, Fulmer J, Seamonds B, et al. Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. J Clin Psychiatry. 2004;65:1491\u20138.","journal-title":"J Clin Psychiatry"},{"key":"2027_CR4","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:273\u201388.","journal-title":"J Clin Endocrinol Metab"},{"key":"2027_CR5","doi-asserted-by":"publisher","first-page":"e12888","DOI":"10.1111\/jne.12888","volume":"32","author":"F Lopez-Vicchi","year":"2020","unstructured":"Lopez-Vicchi F, De Winne C, Brie B, Sorianello E, Ladyman SR, Becu-Villalobos D. Metabolic functions of prolactin: Physiological and pathological aspects. J Neuroendocrinol. 2020;32:e12888.","journal-title":"J Neuroendocrinol"},{"key":"2027_CR6","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3109\/00048674.2011.589044","volume":"45","author":"WJ Inder","year":"2011","unstructured":"Inder WJ, Castle D. Antipsychotic-induced hyperprolactinaemia. Aust N. Z J Psychiatry. 2011;45:830\u20137.","journal-title":"Aust N. Z J Psychiatry"},{"key":"2027_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1677\/JOE-10-0069","volume":"206","author":"S Bernichtein","year":"2010","unstructured":"Bernichtein S, Touraine P, Goffin V. New concepts in prolactin biology. J Endocrinol. 2010;206:1\u201311.","journal-title":"J Endocrinol"},{"key":"2027_CR8","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S2215-0366(21)00241-8","volume":"8","author":"H Taipale","year":"2021","unstructured":"Taipale H, Solmi M, L\u00e4hteenvuo M, Tanskanen A, Correll CU, Tiihonen J. Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland. Lancet Psychiatry. 2021;8:883\u201391.","journal-title":"Lancet Psychiatry"},{"key":"2027_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4103\/IJPSYM.IJPSYM_147_17","volume":"40","author":"D Raveendranthan","year":"2018","unstructured":"Raveendranthan D, Rao NP, Rao MG, Mangot AG, Varambally S, Kesavan M, et al. Add-on Aripiprazole for Atypical Antipsychotic-induced, Clinically Significant Hyperprolactinemia. Indian J Psychol Med. 2018;40:38\u201340.","journal-title":"Indian J Psychol Med"},{"key":"2027_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.psychres.2015.12.033","volume":"237","author":"Y Qiao","year":"2016","unstructured":"Qiao Y, Yang F, Li C, Guo Q, Wen H, Zhu S, et al. Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone. Psychiatry Res. 2016;237:83\u20139.","journal-title":"Psychiatry Res"},{"key":"2027_CR11","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.schres.2008.09.019","volume":"107","author":"MJ Byerly","year":"2009","unstructured":"Byerly MJ, Marcus RN, Tran QV, Eudicone JM, Whitehead R, Baker RA. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophr Res. 2009;107:218\u201322.","journal-title":"Schizophr Res"},{"key":"2027_CR12","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.2147\/NDT.S306573","volume":"17","author":"M Ichinose","year":"2021","unstructured":"Ichinose M, Miura I, Horikoshi S, Yamamoto S, Kanno-Nozaki K, Watanabe K, et al. Effect of Switching to Brexpiprazole on Plasma Homovanillic Acid Levels and Antipsychotic-Related Side Effects in Patients with Schizophrenia or Schizoaffective Disorder. Neuropsychiatr Dis Treat. 2021;17:1047\u201353.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2027_CR13","doi-asserted-by":"publisher","first-page":"423","DOI":"10.9758\/cpn.2019.17.3.423","volume":"17","author":"YS Woo","year":"2019","unstructured":"Woo YS, Yoon BH, Jeon BH, Seo JS, Nam B, Lee SY, et al. Switching Antipsychotics to Blonanserin in Patients with Schizophrenia: An Open-label, Prospective, Multicenter Study. Clin Psychopharmacol Neurosci. 2019;17:423\u201331.","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"2027_CR14","doi-asserted-by":"publisher","first-page":"1.","DOI":"10.1186\/s12991-014-0039-6","volume":"14","author":"N Hashimoto","year":"2015","unstructured":"Hashimoto N, Toyomaki A, Honda M, Miyano S, Nitta N, Sawayama H, et al. Long-term efficacy and tolerability of quetiapine in patients with schizophrenia who switched from other antipsychotics because of inadequate therapeutic response-a prospective open-label study. Ann Gen Psychiatry. 2015;14:1.","journal-title":"Ann Gen Psychiatry"},{"key":"2027_CR15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1055\/s-0028-1112134","volume":"42","author":"V Ryckmans","year":"2009","unstructured":"Ryckmans V, Kahn JP, Modell S, Werner C, McQuade RD, Kerselaers W, et al. Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and\/or safety\/tolerability issues with risperidone: a randomized, multicentre, open-label study. Pharmacopsychiatry. 2009;42:114\u201321.","journal-title":"Pharmacopsychiatry."},{"key":"2027_CR16","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1097\/JCP.0b013e3181842586","volume":"28","author":"H Takeuchi","year":"2008","unstructured":"Takeuchi H, Suzuki T, Uchida H, Nakajima S, Nomura K, Kikuchi T, et al. A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering. J Clin Psychopharmacol. 2008;28:540\u20133.","journal-title":"J Clin Psychopharmacol"},{"key":"2027_CR17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.psychres.2007.02.014","volume":"159","author":"MJ Byerly","year":"2008","unstructured":"Byerly MJ, Nakonezny PA, Rush AJ. Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: A randomized double-blind pilot trial. Psychiatry Res. 2008;159:115\u201320.","journal-title":"Psychiatry Res"},{"key":"2027_CR18","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.psyneuen.2005.12.006","volume":"31","author":"BJ Kinon","year":"2006","unstructured":"Kinon BJ, Ahl J, Liu-Seifert H, Maguire GA. Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology. 2006;31:577\u201388.","journal-title":"Psychoneuroendocrinology."},{"key":"2027_CR19","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1176\/jnp.15.3.375","volume":"15","author":"H Takahashi","year":"2003","unstructured":"Takahashi H, Higuchi H, Kamata M, Naitoh S, Yoshida K, Shimizu T, et al. Effectiveness of switching to quetiapine for neuroleptic-induced amenorrhea. J Neuropsychiatry Clin Neurosci. 2003;15:375\u20137.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"2027_CR20","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0924-977X(99)00040-1","volume":"9","author":"M Markianos","year":"1999","unstructured":"Markianos M, Hatzimanolis J, Lykouras L. Switch from neuroleptics to clozapine does not influence pituitary-gonadal axis hormone levels in male schizophrenic patients. Eur Neuropsychopharmacol. 1999;9:533\u20136.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2027_CR21","first-page":"1571","volume":"10","author":"K Hashimoto","year":"2014","unstructured":"Hashimoto K, Sugawara N, Ishioka M, Nakamura K, Yasui-Furukori N. The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study. Neuropsychiatr Dis Treat. 2014;10:1571\u20136.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2027_CR22","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1037\/a0033448","volume":"21","author":"CS Kalkavoura","year":"2013","unstructured":"Kalkavoura CS, Michopoulos I, Arvanitakis P, Theodoropoulou P, Dimopoulou K, Tzebelikos E, et al. Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients. Exp Clin Psychopharmacol. 2013;21:332\u201341.","journal-title":"Exp Clin Psychopharmacol"},{"key":"2027_CR23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/00004714-198101000-00002","volume":"1","author":"LJ Siever","year":"1981","unstructured":"Siever LJ. The effect of amantadine on prolactin levels and galactorrhea on neuroleptic-treated patients. J Clin Psychopharmacol. 1981;1:2\u20137.","journal-title":"J Clin Psychopharmacol"},{"key":"2027_CR24","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1176\/appi.ajp.2012.11091432","volume":"169","author":"RR Wu","year":"2012","unstructured":"Wu RR, Jin H, Gao K, Twamley EW, Ou JJ, Shao P, et al. Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 2012;169:813\u201321.","journal-title":"Am J Psychiatry"},{"key":"2027_CR25","doi-asserted-by":"publisher","first-page":"7901670","DOI":"10.1155\/2017\/7901670","volume":"2017","author":"P Yang","year":"2017","unstructured":"Yang P, Li L, Yang D, Wang C, Peng H, Huang H, et al. Effect of Peony-Glycyrrhiza Decoction on Amisulpride-Induced Hyperprolactinemia in Women with Schizophrenia: A Preliminary Study. Evid Based Complement Altern Med. 2017;2017:7901670.","journal-title":"Evid Based Complement Altern Med"},{"key":"2027_CR26","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/JCP.0000000000000607","volume":"36","author":"SC Man","year":"2016","unstructured":"Man SC, Li XB, Wang HH, Yuan HN, Wang HN, Zhang RG, et al. Peony-Glycyrrhiza Decoction for Antipsychotic-Related Hyperprolactinemia in Women With Schizophrenia: A Randomized Controlled Trial. J Clin Psychopharmacol. 2016;36:572\u20139.","journal-title":"J Clin Psychopharmacol"},{"key":"2027_CR27","first-page":"1440","volume":"34","author":"S-Y Xia","year":"2014","unstructured":"Xia S-Y, Zhang Y-R, Yu H, Meng X, Zhang P, Liu J. Treatment of antipsychotic drug-induced phlegm dampness type amenorrhea by Wuji Powder and a small dose aripiprazole: a clinical study. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chin J Integr traditional West Med \/ Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu ban. 2014;34:1440\u20133.","journal-title":"Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chin J Integr traditional West Med \/ Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu ban"},{"key":"2027_CR28","first-page":"2587","volume":"31","author":"R Yu","year":"2010","unstructured":"Yu R, Qi Y, Hou C, Jia F. Efficacy of Bupleurum Reconcile Soup in treatment of antipsychotics-induced hyperprolactinemia. Guangdong Med J. 2010;31:2587\u20139.","journal-title":"Guangdong Med J"},{"key":"2027_CR29","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1097\/00004714-199908000-00018","volume":"19","author":"K Yamada","year":"1999","unstructured":"Yamada K, Kanba S, Yagi G, Asai M. Herbal medicine (Shakuyaku-kanzo-to) in the treatment of risperidone-induced amenorrhea. J Clin Psychopharmacol. 1999;19:380\u20131.","journal-title":"J Clin Psychopharmacol"},{"key":"2027_CR30","doi-asserted-by":"publisher","first-page":"681418","DOI":"10.3389\/fpsyt.2021.681418","volume":"12","author":"C Zhuo","year":"2021","unstructured":"Zhuo C, Xu Y, Wang H, Fang T, Chen J, Zhou C, et al. Safety and Efficacy of High-Dose Vitamin B6 as an Adjunctive Treatment for Antipsychotic-Induced Hyperprolactinemia in Male Patients With Treatment-Resistant Schizophrenia. Front Psychiatry. 2021;12:681418.","journal-title":"Front Psychiatry"},{"key":"2027_CR31","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/ajo.12479","volume":"56","author":"M Snellen","year":"2016","unstructured":"Snellen M, Power J, Blankley G, Galbally M. Pharmacological lactation suppression with D2 receptor agonists and risk of postpartum psychosis: A systematic review. Aust N. Z J Obstet Gynaecol. 2016;56:336\u201340.","journal-title":"Aust N. Z J Obstet Gynaecol"},{"key":"2027_CR32","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.schres.2020.04.031","volume":"222","author":"J Labad","year":"2020","unstructured":"Labad J, Montalvo I, Gonz\u00e1lez-Rodr\u00edguez A, Garc\u00eda-Rizo C, Crespo-Facorro B, Monreal JA, et al. Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia: A systematic review and meta-analysis. Schizophr Res. 2020;222:88\u201396.","journal-title":"Schizophr Res"},{"key":"2027_CR33","first-page":"4","volume":"27","author":"M Meng","year":"2015","unstructured":"Meng M, Li W, Zhang S, Wang H, Sheng J, Wang J, et al. Using aripiprazole to reduce antipsychotic-induced hyperprolactinemia: meta-analysis of currently available randomized controlled trials. Shanghai Arch Psychiatry. 2015;27:4\u201317.","journal-title":"Shanghai Arch Psychiatry"},{"key":"2027_CR34","doi-asserted-by":"publisher","first-page":"105904","DOI":"10.1016\/j.dib.2020.105904","volume":"31","author":"J Labad","year":"2020","unstructured":"Labad J, Montalvo I, Gonz\u00e1lez-Rodr\u00edguez A, Garc\u00eda-Rizo C, Crespo-Facorro B, Monreal JA, et al. Data of a meta-analysis on pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia. Data Brief. 2020;31:105904.","journal-title":"Data Brief"},{"key":"2027_CR35","doi-asserted-by":"publisher","first-page":"e100003","DOI":"10.1136\/gpsych-2018-100003","volume":"31","author":"W Zheng","year":"2018","unstructured":"Zheng W, Cai DB, Li HY, Wu YJ, Ng CH, Ungvari GS, et al. Adjunctive Peony-Glycyrrhiza decoction for antipsychotic-induced hyperprolactinaemia: a meta-analysis of randomised controlled trials. Gen Psychiatr. 2018;31:e100003.","journal-title":"Gen Psychiatr"},{"key":"2027_CR36","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1177\/0269881117699630","volume":"31","author":"W Zheng","year":"2017","unstructured":"Zheng W, Yang XH, Cai DB, Ungvari GS, Ng CH, Wang N, et al. Adjunctive metformin for antipsychotic-related hyperprolactinemia: A meta-analysis of randomized controlled trials. J Psychopharmacol. 2017;31:625\u201331.","journal-title":"J Psychopharmacol"},{"key":"2027_CR37","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.psychres.2016.01.031","volume":"237","author":"QJ Bo","year":"2016","unstructured":"Bo QJ, Wang ZM, Li XB, Ma X, Wang CY, de Leon J. Adjunctive metformin for antipsychotic-induced hyperprolactinemia: A systematic review. Psychiatry Res. 2016;237:257\u201363.","journal-title":"Psychiatry Res"},{"key":"2027_CR38","doi-asserted-by":"publisher","first-page":"e70179","DOI":"10.1371\/journal.pone.0070179","volume":"8","author":"X Li","year":"2013","unstructured":"Li X, Tang Y, Wang C. Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials. PloS one. 2013;8:e70179.","journal-title":"PloS one"},{"key":"2027_CR39","doi-asserted-by":"publisher","first-page":"728204","DOI":"10.3389\/fpsyt.2021.728204","volume":"12","author":"L Zhang","year":"2021","unstructured":"Zhang L, Qi H, Xie YY, Zheng W, Liu XH, Cai DB, et al. Efficacy and Safety of Adjunctive Aripiprazole, Metformin, and Paeoniae-Glycyrrhiza Decoction for Antipsychotic-Induced Hyperprolactinemia: A Network Meta-Analysis of Randomized Controlled Trials. Front Psychiatry. 2021;12:728204.","journal-title":"Front Psychiatry"},{"key":"2027_CR40","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","volume":"331","author":"DM Caldwell","year":"2005","unstructured":"Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. Bmj. 2005;331:897\u2013900.","journal-title":"Bmj."},{"key":"2027_CR41","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73:712\u20136.","journal-title":"ANZ J Surg"},{"key":"2027_CR42","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. Bmj. 2019;366:l4898.","journal-title":"Bmj."},{"key":"2027_CR43","doi-asserted-by":"publisher","first-page":"m3900","DOI":"10.1136\/bmj.m3900","volume":"371","author":"R Brignardello-Petersen","year":"2020","unstructured":"Brignardello-Petersen R, Florez ID, Izcovich A, Santesso N, Hazlewood G, Alhazanni W, et al. GRADE approach to drawing conclusions from a network meta-analysis using a minimally contextualised framework. Bmj. 2020;371:m3900.","journal-title":"Bmj."},{"key":"2027_CR44","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22:153\u201360.","journal-title":"Evid Based Ment Health"},{"key":"2027_CR45","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/jrsm.1054","volume":"3","author":"G van Valkenhoef","year":"2012","unstructured":"van Valkenhoef G, Lu G, de Brock B, Hillege H, Ades AE, Welton NJ. Automating network meta-analysis. Res Synth Methods. 2012;3:285\u201399.","journal-title":"Res Synth Methods"},{"key":"2027_CR46","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1210\/jcem-42-6-1192","volume":"42","author":"EN McIntosh","year":"1976","unstructured":"McIntosh EN. Treatment of women with the galactorrhea-amenorrhea syndrome with pyridoxine (vitamin B6). J Clin Endocrinol Metab. 1976;42:1192\u20135.","journal-title":"J Clin Endocrinol Metab"},{"key":"2027_CR47","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1055\/s-2007-1013447","volume":"17","author":"PP Vescovi","year":"1985","unstructured":"Vescovi PP, Gerra G, Rastelli G, Ceresini G, Moccia G. Pyridoxine (Vit. B6) decreases opioids-induced hyperprolactinemia. Horm Metab Res. 1985;17:46\u20137.","journal-title":"Horm Metab Res"},{"key":"2027_CR48","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1210\/jcem-46-4-686","volume":"46","author":"AM Spiegel","year":"1978","unstructured":"Spiegel AM, Rosen SW, Weintraub BD, Marynick SP. Effect of intravenous pyridoxine on plasma prolactin in hyperprolactinemic subjects. J Clin Endocrinol Metab. 1978;46:686\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"2027_CR49","first-page":"293","volume":"53","author":"JM de Waal","year":"1978","unstructured":"de Waal JM, Steyn AF, Harms JH, Slabber CF, Pannall PR. Failure of pyridoxine to suppress raised serum prolactin levels. S Afr Med J. 1978;53:293\u20134.","journal-title":"S Afr Med J"},{"key":"2027_CR50","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/BF03350421","volume":"2","author":"F Brambilla","year":"1979","unstructured":"Brambilla F, Penati G, Freni S, Bottinelli S, Maffei C, Maiella V. Failure of pyridoxine to effect neuroleptic-induced hyperprolactinemia in psychotic patients. J Endocrinol Investig. 1979;2:299\u2013302.","journal-title":"J Endocrinol Investig"},{"key":"2027_CR51","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3390\/molecules14010329","volume":"14","author":"S Mooney","year":"2009","unstructured":"Mooney S, Leuendorf JE, Hendrickson C, Hellmann H. Vitamin B6: a long known compound of surprising complexity. Molecules. 2009;14:329\u201351.","journal-title":"Molecules."},{"key":"2027_CR52","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.2147\/TCRM.S274122","volume":"16","author":"CA Calderon-Ospina","year":"2020","unstructured":"Calderon-Ospina CA, Nava-Mesa MO, Paez-Hurtado AM. Update on Safety Profiles of Vitamins B1, B6, and B12: A Narrative Review. Ther Clin Risk Manag. 2020;16:1275\u201388.","journal-title":"Ther Clin Risk Manag."},{"key":"2027_CR53","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.schres.2018.12.008","volume":"206","author":"Y Gao","year":"2019","unstructured":"Gao Y, Li M, Luo J, Yang Y, Li Z, Li Y, et al. Pyridoxine for the treatment of quetiapine-induced hyperprolactinemia and amenorrhea: A case report. Schizophr Res. 2019;206:448\u20139.","journal-title":"Schizophr Res"},{"key":"2027_CR54","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1440-1819.2010.02156.x","volume":"65","author":"CY Chen","year":"2011","unstructured":"Chen CY, Lin TY, Wang CC, Shuai HA. Improvement of serum prolactin and sexual function after switching to aripiprazole from risperidone in schizophrenia: a case series. Psychiatry Clin Neurosci. 2011;65:95\u20137.","journal-title":"Psychiatry Clin Neurosci"},{"key":"2027_CR55","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1016\/j.pnpbp.2008.09.016","volume":"32","author":"ML Lu","year":"2008","unstructured":"Lu ML, Shen WW, Chen CH. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1978\u201381.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2027_CR56","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.pnpbp.2006.02.001","volume":"30","author":"BH Lee","year":"2006","unstructured":"Lee BH, Kim YK, Park SH. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:714\u20137.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2027_CR57","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1055\/s-2005-837766","volume":"38","author":"M Nakajima","year":"2005","unstructured":"Nakajima M, Terao T, Iwata N, Nakamura J. Switching female schizophrenic patients to quetiapine from conventional antipsychotic drugs: effects on hyperprolactinemia. Pharmacopsychiatry. 2005;38:17\u20139.","journal-title":"Pharmacopsychiatry."},{"key":"2027_CR58","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/WNF.0000000000000006","volume":"36","author":"K Kawabe","year":"2013","unstructured":"Kawabe K, Horiuchi F, Ueno SI. Blonanserin, a novel antipsychotic, is suitable for treating schizophrenia associated with hyperprolactinemia: A case series. Clin Neuropharmacol. 2013;36:239\u201341.","journal-title":"Clin Neuropharmacol"},{"key":"2027_CR59","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/S0278-5846(98)00064-5","volume":"22","author":"J Hatzimanolis","year":"1998","unstructured":"Hatzimanolis J, Lykouras L, Markianos M, Oulis P. Neurochemical variables in schizophrenic patients during switching from neuroleptics to clozapine. Prog Neuropsychopharmacol Biol Psychiatry. 1998;22:1077\u201385.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2027_CR60","doi-asserted-by":"publisher","first-page":"408","DOI":"10.4088\/JCP.v63n0506","volume":"63","author":"KS Kim","year":"2002","unstructured":"Kim KS, Pae CU, Chae JH, Bahk WM, Jun TY, Kim DJ, et al. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J Clin Psychiatry. 2002;63:408\u201313.","journal-title":"J Clin Psychiatry"},{"key":"2027_CR61","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/j.1440-1819.2009.02036.x","volume":"64","author":"H Takeuchi","year":"2010","unstructured":"Takeuchi H, Uchida H, Suzuki T, Watanabe K, Kashima H. Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: One-year follow-up study. Psychiatry Clin Neurosci. 2010;64:104\u20136.","journal-title":"Psychiatry Clin Neurosci"},{"key":"2027_CR62","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/YIC.0000000000000136","volume":"31","author":"YS Woo","year":"2016","unstructured":"Woo YS, Bahk WM, Park YM, Chung S, Yoon BH, Won S, et al. Effects of switching to aripiprazole from current atypical antipsychotics on subsyndromal symptoms and tolerability in patients with bipolar disorder. Int Clin Psychopharmacol. 2016;31:275\u201386.","journal-title":"Int Clin Psychopharmacol"},{"key":"2027_CR63","doi-asserted-by":"publisher","first-page":"114030","DOI":"10.1016\/j.psychres.2021.114030","volume":"302","author":"DL Kelly","year":"2021","unstructured":"Kelly DL, Claxton A, Bidollari I, Du Y. Analysis of prolactin and sexual side effects in patients with schizophrenia who switched from paliperidone palmitate to aripiprazole lauroxil. Psychiatry Res. 2021;302:114030.","journal-title":"Psychiatry Res"},{"key":"2027_CR64","doi-asserted-by":"publisher","first-page":"S306","DOI":"10.1016\/S0924-977X(00)80349-1","volume":"10","author":"BJ Kinon","year":"2000","unstructured":"Kinon BJ, Basson B, Wang J, Malcolm SK, Stauffer VL. Rapid reduction in hyperprolactinemia upon switching treatment to olanzapine from conventional antipsychotic drugs or risperidone. Eur Neuropsychopharmacol. 2000;10:S306\u2013S.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2027_CR65","doi-asserted-by":"publisher","first-page":"S544","DOI":"10.1016\/S0924-977X(09)70867-3","volume":"19","author":"AL Montejo","year":"2009","unstructured":"Montejo AL, Majadas S, Franco M, Prieto N, Alvarez P, Gordo R, et al. Changes in hyperprolactinaemia and related adverse events after switching antipsychotic treatment to quetiapine. Eur Neuropsychopharmacol. 2009;19:S544\u2013S5.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2027_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-020-02957-7","volume":"20","author":"YW Jen","year":"2020","unstructured":"Jen YW, Hwang TJ, Chan HY, Hsieh MH, Liu CC, Liu CM, et al. Abnormally low prolactin levels in schizophrenia patients after switching to aripiprazole in a randomized trial: a biomarker for rebound in psychotic symptoms? BMC Psychiatry. 2020;20:552.","journal-title":"BMC Psychiatry"},{"key":"2027_CR67","doi-asserted-by":"publisher","first-page":"S488","DOI":"10.1016\/S0924-977X(09)70770-9","volume":"19","author":"SW Kim","year":"2009","unstructured":"Kim SW, Lee JH, Lee YH, Chung KH, Ryu JH, Yoon JS, et al. Switching to aripiprazole from atypical antipsychotics in patients with schizophrenia. Eur Neuropsychopharmacol. 2009;19:S488\u2013S9.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2027_CR68","first-page":"59","volume":"15","author":"M Nishimoto","year":"2012","unstructured":"Nishimoto M, Ishigaki T, Koyama Y, Nishimoto K, Funaki K, Matsunaga Y, et al. Sexual dysfunction and changes in satisfaction with switch to aripiprazole. Int J Neuropsychopharmacol. 2012;15:59.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2027_CR69","first-page":"74","volume":"50","author":"J Fujioi","year":"2017","unstructured":"Fujioi J, Iwamoto K, Banno M, Kikuchi T, Aleksic B, Ozaki N. Effect of Adjunctive Aripiprazole on Sexual Dysfunction in Schizophrenia: A Preliminary Open-Label Study. Pharmacopsychiatry 2017;50:74\u20138.","journal-title":"Pharmacopsychiatry"},{"key":"2027_CR70","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1097\/JCP.0b013e3182970431","volume":"33","author":"M Ziadi Trives","year":"2013","unstructured":"Ziadi Trives M, Bonete Ll\u00e1cer JM, Garc\u00eda Escudero MA, Mart\u00ednez, Pastor CJ. Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection. J Clin Psychopharmacol. 2013;33:538\u201341.","journal-title":"J Clin Psychopharmacol"},{"key":"2027_CR71","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/JCP.0b013e318205e1aa","volume":"31","author":"M van Kooten","year":"2011","unstructured":"van Kooten M, Arends J, Cohen D. Preliminary report: a naturalistic study of the effect of aripiprazole addition on risperidone-related hyperprolactinemia in patients treated with risperidone long-acting injection. J Clin Psychopharmacol. 2011;31:126\u20138.","journal-title":"J Clin Psychopharmacol"},{"key":"2027_CR72","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1097\/JCP.0b013e3181ee832d","volume":"30","author":"N Yasui-Furukori","year":"2010","unstructured":"Yasui-Furukori N, Furukori H, Sugawara N, Fujii A, Kaneko S. Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. J Clin Psychopharmacol. 2010;30:596\u20139.","journal-title":"J Clin Psychopharmacol"},{"key":"2027_CR73","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.pnpbp.2010.08.012","volume":"34","author":"CK Chen","year":"2010","unstructured":"Chen CK, Huang YS, Ree SC, Hsiao CC. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:1495\u20139.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2027_CR74","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.4088\/JCP.08l04671","volume":"70","author":"JX Chen","year":"2009","unstructured":"Chen JX, Su YA, Wang SL, Bian QT, Liu YH, Wang N, et al. Aripiprazole Treatment of Risperidone-Induced Hyperprolactinemia. J Clin Psychiatry. 2009;70:1058\u20139.","journal-title":"J Clin Psychiatry"},{"key":"2027_CR75","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.schres.2021.01.012","volume":"228","author":"A Arnaiz","year":"2021","unstructured":"Arnaiz A, Zum\u00e1rraga M, Erkoreka L, Olivas O, Arrue A, Zamalloa MI, et al. Factors influencing the effect of aripiprazole on prolactin levels in patients treated with risperidone or paliperidone. Sex seems to matter. Schizophr Res. 2021;228:382\u20134.","journal-title":"Schizophr Res"},{"key":"2027_CR76","first-page":"307","volume":"37","author":"DU Jung","year":"2011","unstructured":"Jung DU, Kelly DL, Kong BG, Kang JW, Oh MK, Seo BJ, et al. Adjunctive treatment with aripiprazole for risperidone-induced amenrrhea. Schizophrenia Bull. 2011;37:307.","journal-title":"Schizophrenia Bull"},{"key":"2027_CR77","first-page":"S53","volume":"52","author":"PB Sajeev Kumar","year":"2010","unstructured":"Sajeev Kumar PB, Rao NP, Venkatasubramanian G, Arasappa R, Behere RV, Vishwanath BV, et al. Aripiprazole in treatment of antipsychotic-induced hyperprolactinemia. Indian J Psychiatry. 2010;52:S53.","journal-title":"Indian J Psychiatry"},{"key":"2027_CR78","doi-asserted-by":"publisher","first-page":"92","DOI":"10.2174\/157488612802715753","volume":"7","author":"R Coronas","year":"2012","unstructured":"Coronas R, Cobo J, Gim\u00e9nez-Palop O, Ortega E, M\u00e1rquez M. Safety of cabergoline in the management of pituitary prolactin-induced symptoms with patients treated with atypical neuroleptics. Curr Drug Saf. 2012;7:92\u20138.","journal-title":"Curr Drug Saf"},{"key":"2027_CR79","doi-asserted-by":"publisher","first-page":"187","DOI":"10.4088\/JCP.v65n0207","volume":"65","author":"R Cavallaro","year":"2004","unstructured":"Cavallaro R, Cocchi F, Angelone SM, Lattuada E, Smeraldi E. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry. 2004;65:187\u201390.","journal-title":"J Clin Psychiatry"},{"key":"2027_CR80","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1055\/s-2004-827176","volume":"37","author":"N Bliesener","year":"2004","unstructured":"Bliesener N, Yokusoglu H, Quednow BB, Klingm\u00fcller D, K\u00fchn KU. Usefulness of bromocriptine in the treatment of amisulpride-induced hyperprolactinemia: A case report. Pharmacopsychiatry. 2004;37:189\u201391.","journal-title":"Pharmacopsychiatry."},{"key":"2027_CR81","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1159\/000118184","volume":"13","author":"JB Cohn","year":"1985","unstructured":"Cohn JB, Brust J, DiSerio F, Singer J. Effect of bromocriptine mesylate on induced hyperprolactinemia in stabilized psychiatric outpatients undergoing neuroleptic treatment. Neuropsychobiology. 1985;13:173\u20139.","journal-title":"Neuropsychobiology."},{"key":"2027_CR82","doi-asserted-by":"publisher","first-page":"60","DOI":"10.9758\/cpn.2013.11.2.60","volume":"11","author":"BJ Lee","year":"2013","unstructured":"Lee BJ, Lee SJ, Kim MK, Lee JG, Park SW, Kim GM, et al. Effect of aripiprazole on cognitive function and hyperprolactinemia in patients with schizophrenia treated with risperidone. Clin Psychopharmacol Neurosci. 2013;11:60\u20136.","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"2027_CR83","first-page":"625","volume":"33","author":"P Huang","year":"2011","unstructured":"Huang P, Yang Z. Controlled observation of traditional Chinese medicine Xuefuzhuyu decoction combined with aripiprazole in treatment of schizophrenic patients with antipsychotic-induced amenorrhea. Acta Academiae Medicinae Militaris Tertiae. 2011;33:625\u20137.","journal-title":"Acta Academiae Medicinae Militaris Tertiae"},{"key":"2027_CR84","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/JCP.0000000000000426","volume":"35","author":"TJ Hwang","year":"2015","unstructured":"Hwang TJ, Lo WM, Chan HY, Lin CF, Hsieh MH, Liu CC, et al. Fast versus slow strategy of switching patients with schizophrenia to aripiprazole from other antipsychotics. J Clin Psychopharmacol. 2015;35:635\u201344.","journal-title":"J Clin Psychopharmacol"},{"key":"2027_CR85","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.psyneuen.2015.04.011","volume":"58","author":"JX Chen","year":"2015","unstructured":"Chen JX, Su YA, Bian QT, Wei LH, Zhang RZ, Liu YH, et al. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study. Psychoneuroendocrinology. 2015;58:130\u201340.","journal-title":"Psychoneuroendocrinology."},{"key":"2027_CR86","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1176\/appi.ajp.2007.06071075","volume":"164","author":"JC Shim","year":"2007","unstructured":"Shim JC, Shin JG, Kelly DL, Jung DU, Seo YS, Liu KH, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry. 2007;164:1404\u201310.","journal-title":"Am J Psychiatry"},{"key":"2027_CR87","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/JCP.0000000000000898","volume":"38","author":"DL Kelly","year":"2018","unstructured":"Kelly DL, Powell MM, Wehring HJ, Sayer MA, Kearns AM, Hackman AL, et al. Adjunct Aripiprazole Reduces Prolactin and Prolactin-Related Adverse Effects in Premenopausal Women With Psychosis: results From the DAAMSEL Clinical Trial. J Clin Psychopharmacol. 2018;38:317\u201326.","journal-title":"J Clin Psychopharmacol"},{"key":"2027_CR88","doi-asserted-by":"publisher","first-page":"e0139717","DOI":"10.1371\/journal.pone.0139717","volume":"10","author":"J Zhao","year":"2015","unstructured":"Zhao J, Song X, Ai X, Gu X, Huang G, Li X, et al. Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical Trial. PloS One. 2015;10:e0139717.","journal-title":"PloS One"},{"key":"2027_CR89","first-page":"718","volume":"15","author":"LPJJ Xu","year":"2006","unstructured":"Xu LPJJ, Shi H. A control study of aripiprazole in the treatment of hyperprolactinemia by antipsychotics origin. Chin J Behav Med Sci. 2006;15:718\u201320.","journal-title":"Chin J Behav Med Sci"},{"key":"2027_CR90","first-page":"169","volume":"41","author":"JY Ji","year":"2008","unstructured":"Ji JY, Song ZX, Lp X. Aripiprazole in treatment of female schizophrenics with risperidone induced hyperprolactinemia. Chin J Psychiatry. 2008;41:169\u201371.","journal-title":"Chin J Psychiatry"},{"key":"2027_CR91","first-page":"224","volume":"42","author":"HZ Chen","year":"2009","unstructured":"Chen HZ, Niu FRQM. Effect of aripiprazole on the hyperprolactinmia induced by risperidone in male schizophrenia patients. Chin J Psychiatry. 2009;42:224\u20137.","journal-title":"Chin J Psychiatry"},{"key":"2027_CR92","first-page":"843","volume":"31","author":"Z Liu","year":"2011","unstructured":"Liu Z, Cao B, Jiao F, Li D, Chen H, Liu W. A control study of aripiprazole in the treatment for antipsychotics-induced hyperprolactinemia. Chin J Hospital Pharm. 2011;31:843\u20136.","journal-title":"Chin J Hospital Pharm"},{"key":"2027_CR93","first-page":"811","volume":"23","author":"J Chen","year":"2014","unstructured":"Chen J, Zhang R, Li W, Liu Y, Jiang L, Bian Q, et al. Adjunctive treatment of risperidone-induced hyperprolactinemia with aripiprazole: a randomized, double-blind, placebo-controlled study. Chin J N. Drugs. 2014;23:811\u20134.","journal-title":"Chin J N. Drugs"},{"key":"2027_CR94","first-page":"1300","volume":"23","author":"J Liang","year":"2014","unstructured":"Liang J, Yan J, Zhang X. Aripirazole reduces paliperidone-induced increase of prolactin in patients with schizophrenia: a randomized, double blind and placebo-controlled study. Chin J N. Drugs. 2014;23:1300\u20133,10.","journal-title":"Chin J N. Drugs."},{"key":"2027_CR95","first-page":"1035","volume":"13","author":"H Wang","year":"2014","unstructured":"Wang H, Zhang J, Wen S, Zhao J. Effects of various doses of aripiprazole on antipsychotics-induced hyperprolactinemia: an add-on therapy study. Chin J Neuromed. 2014;13:1035\u20138.","journal-title":"Chin J Neuromed"},{"key":"2027_CR96","first-page":"297","volume":"48","author":"C Xu","year":"2015","unstructured":"Xu C, Huang W, Zhao X, Liang Z, Deng W. Effect of various doses aripiprazole on hyperprolactinemia induced by amisulpride and risperidone. Chin J Psychiatry. 2015;48:297\u2013302.","journal-title":"Chin J Psychiatry"},{"key":"2027_CR97","first-page":"569","volume":"25","author":"H Chen","year":"2016","unstructured":"Chen H, Zhang R, Chen J, Liu Y, Li W, Tan Y, et al. Dose-effect relationship of aripiprazole on hyperprolactinemia induced by risperidone in female patients. Chin J N. Drugs. 2016;25:569\u201373.","journal-title":"Chin J N. Drugs"},{"key":"2027_CR98","first-page":"334","volume":"27","author":"L Zhang","year":"2018","unstructured":"Zhang L, Li Y, Liu Y, Chen J, Liu Y, Zhang R, et al. Dose-effect relationship of aripiprazole on hyperprolactinemia induced by risperidone in male patients. Chin J N. Drugs. 2018;27:334\u20138.","journal-title":"Chin J N. Drugs"},{"key":"2027_CR99","first-page":"417","volume":"27","author":"J Xia","year":"2011","unstructured":"Xia J, Wang Y, Gan J, Cao S, Duan D, Qian P, et al. Efficacy of metformin combined behavior intervention in the treatment of metabolic disorders caused by risperidone. Chin J Clin Pharmacol. 2011;27:417\u20139.","journal-title":"Chin J Clin Pharmacol"},{"key":"2027_CR100","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/JCP.0b013e318172473c","volume":"28","author":"HN Yuan","year":"2008","unstructured":"Yuan HN, Wang CY, Sze CW, Tong Y, Tan QR, Feng XJ, et al. A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. J Clin Psychopharmacol. 2008;28:264\u2013370.","journal-title":"J Clin Psychopharmacol"},{"key":"2027_CR101","first-page":"1456","volume":"36","author":"P Gu","year":"2016","unstructured":"Gu P, Jin X, Li X, Wu YQ, Mao FQ. [Treatment of Olanzapine-induced Hyperprolactinemia by Shaoyao Gancao Decoction]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2016;36:1456\u20139.","journal-title":"Zhongguo Zhong Xi Yi Jie He Za Zhi"},{"key":"2027_CR102","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/WNF.0000000000000175","volume":"39","author":"HW Yoon","year":"2016","unstructured":"Yoon HW, Lee JS, Park SJ, Lee SK, Choi WJ, Kim TY, et al. Comparing the Effectiveness and Safety of the Addition of and Switching to Aripiprazole for Resolving Antipsychotic-Induced Hyperprolactinemia: A Multicenter, Open-Label, Prospective Study. Clin Neuropharmacol. 2016;39:288\u201394.","journal-title":"Clin Neuropharmacol"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-02027-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-02027-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-02027-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T19:42:42Z","timestamp":1669232562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-02027-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,5]]},"references-count":102,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2027"],"URL":"https:\/\/doi.org\/10.1038\/s41398-022-02027-4","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,5]]},"assertion":[{"value":"7 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"267"}}